Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego
CA
92121
United States
Tel: 858-453-7200
Fax: 858-453-7210
Website: http://www.arenapharm.com/
Email: invest@arenapharm.com
149 articles about Arena Pharmaceuticals, Inc.
-
Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
11/15/2018
Arena will receive $800M upfront, and is eligible to receive low double-digit tiered royalties, plus up to $400M in milestone payments
-
Arena Pharmaceuticals Snags $800 Million from United Therapeutics for a Phase III PAH Drug
11/15/2018
United Therapeutics bets a significant amount of money on the potential commercialization of ralinepag. -
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2018 Financial Results
11/7/2018
Ralinepag open-label extension data demonstrated durable, long-term improvements in both PVR and 6MWD
-
Arena Pharmaceuticals to Release Third Quarter 2018 Financial Results and Provide Corporate Update on November 7
10/31/2018
The Company will host a conference call and live webcast with the investment community the same day at 4:30 p.m. EST.
-
Arena Pharmaceuticals Presented Phase 2 Clinical Data for Etrasimod in Ulcerative Colitis at the American College of Gastroenterology Annual Meeting
10/8/2018
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from its OASIS Phase 2 clinical study for its investigational drug candidate etrasimod, a next-generation, oral, S1P receptor modulator with optimized activity being evaluated in ulcerative colitis (UC), were presented by Dr. William J. Sandborn at the American College of Gastroenterology Annual Meeting.
-
Arena Pharmaceuticals to Host R&D Day on October 4 in New York City
9/21/2018
Arena Pharmaceuticals, Inc. today announced that the Company will host an R&D Day to outline key catalysts and new information on the clinical programs for its potentially first- or best-in-class late-stage investigational compounds: etrasimod in inflammatory bowel disease (IBD), ralinepag in pulmonary arterial hypertension (PAH), and olorinab in visceral pain.
-
Arena Pharmaceuticals to Present at Upcoming October 2018 Investor Conferences
9/20/2018
Arena Pharmaceuticals, Inc. today announced that members of its senior management team will participate in the upcoming investor conferences
-
Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress
9/17/2018
Olorinab is a peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of visceral pain associated with Crohn's disease
-
Arena Pharmaceuticals to Present at Upcoming September 2018 Investor Conferences
8/29/2018
Arena Pharmaceuticals, Inc. today announced that members of its senior management team will participate in the upcoming investor conferences
-
Eisai: Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ
8/28/2018
Presented at The European Society of Cardiology and Published in the New England Journal of Medicine.
-
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2018 Financial Results
8/6/2018
Initiated ADVANCE Phase 3 Program for Ralinepag in Pulmonary Arterial Hypertension (PAH)
-
In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell most of its assets, subject to court approval.
-
Arena Pharmaceuticals to Release Second Quarter 2018 Financial Results and Provide Corporate Update on Monday, August 6
7/30/2018
Arena Pharmaceuticals, Inc. announced that the Company will release its second quarter 2018 financial results and provide a corporate update on Monday, August 6, 2018, after the close of the U.S. financial markets.
-
Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
5/21/2018
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH), will be presented at the American Thoracic Society (ATS) International Conference on May 23.
-
Arena Pharmaceuticals to Present at Upcoming Investor Conferences
5/10/2018
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit D. Munshi, President and Chief Executive Officer, will present at the following investor conferences
-
Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8
5/2/2018
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Company will release its first quarter 2018 financial results and provide a corporate update on Tuesday, May 8, 2018, after the close of the U.S. financial markets
-
Arena Pharmaceuticals and Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound
5/1/2018
- Arena's non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine's expertise in developing products for genitourinary disorders
-
Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting
4/12/2018
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH), will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 2018 Annual Meeting
-
Novartis released full results from its Phase III EXPAND trial of siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS), which it published in the journal The Lancet.
-
Arena Pharmaceuticals is hoping to raise $352 million from a stock offering just days after releasing positive top-line results from its Phase II trial of etrasimod in ulcerative colitis.